Yu Wu

Dr. Yu Wu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
YWYu Wu
Yu Wu
ASAaron Spaulding
Aaron Spaulding
SBShalmali Borkar
Shalmali Borkar
MSMichelle M. Shoaei
Michelle M. Shoaei
MMMaria Mendoza
Maria Mendoza
PFPablo Moreno Franco
Pablo Moreno Franco
To reduce diagnostic blood loss by using small volume tubes for routine laboratory testing throughout the hospital, as blood loss from laboratory testing can be substantial for patients and may lead to hospital-acquired anemia. Diagnostic blood loss was evaluated in hospitalized patients between April 1, 2017, and June 1, 2018. The preintervention, during intervention, and postintervention mean diagnostic blood loss per hospitalized patient was compared across the floors and for each type of tube for hematology, basic metabolic panel, and coagulation tests. Mean hemoglobin levels, blood transfusions per hospitalized patient, and percent redraws were also compared. The total volume of blood drawn for all the 3 tests decreased across each implementation phase; however, only patients admitted to the transplant and critical care (T/CC) units had increased hemoglobin levels. In addition, there was a significant reduction in transfusions across implementation phases. The incidence risk ratio for transfusion reduced even more in patients admitted to the T/CC units. Finally, there was no significant difference in the overall percent redraws across all the units. The use of small volume tubes in exchange for standard sized tubes markedly decreased diagnostic blood loss by 25.7% in all the units and 22.9% in the T/CC units. Also, the number of transfusions decreased across units, with the greatest decrease in the T/CC units. An increase in mean hemoglobin levels was observed specifically in patients admitted to the T/CC units, with no corresponding change in percent redraws across all the units.

18 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YWYu Wu
Yu Wu
LGLina Gao
Lina Gao
JLJose Lazo
Jose Lazo
BMBrandon Martinez
Brandon Martinez
SGSimran Grewal
Simran Grewal
TMTeresa De Marco
Teresa De Marco
Heart transplantation has significantly improved survival and enhanced the quality of life of patients with end-stage heart failure. Successful long-term outcomes are predicated on a collaborative effort among patients, transplant teams, and primary care providers (PCPs). Notably, PCPs are increasingly pivotal in post-transplant care, engaging in annual assessments, early recognition of complications, and referral, thus minimizing morbidity and mortality. This article highlights key considerations for PCPs, including indications for heart transplant, immunosuppressive therapy and infection prophylaxis, management of post-transplant complications, psychosocial and lifestyle adjustment, and family planning. This roadmap aims to empower PCPs to deliver optimal care and improve long-term outcomes for heart transplant recipients.

4 July 2026 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Open access
RRRyan K Ruaysungnoen
Ryan K Ruaysungnoen
ASAnja Strehlow
Anja Strehlow
SBSylvie Baudart
Sylvie Baudart
YWYu Wu
Yu Wu
AFAmy G Fiedler
Amy G Fiedler
COConnor G O’BRien
Connor G O’BRien
Aims: Multiple veno-arterial extracorporeal membrane oxygenation (VA-ECMO) studies have recently reported that early hyperoxia is associated with increased mortality; yet, the underlying mechanism is unclear. As prior analyses did not account for native cardiac output or fraction of delivered oxygen, it remains unknown whether hyperoxia is directly injurious or primarily a surrogate of poor intrinsic cardiac function and proximal mixing. This study aims to evaluate whether hyperoxia is an independent predictor of mortality in VA-ECMO patients or whether it primarily reflects impaired native cardiac function. Methods and results: We conducted a single-centre retrospective cohort study of 227 VA-ECMO patients to evaluate the relationship between hyperoxia and intensive care unit (ICU) mortality, accounting for native cardiac index using multivariable regression and principal component analysis. Average PaO2 and cardiac index were analysed as continuous variables. Decreased cardiac index was the strongest independent predictor of ICU mortality in a multivariable regression [odds ratio (OR) 0.22; 95% confidence interval (CI): 0.06–0.70; P = 0.018]. After adjusting for native cardiac index and utilization of advanced therapies (i.e. heart transplant or left ventricular assist device), the association between hyperoxia and mortality became insignificant. Average PaO2 and cardiac index were strongly inversely collinear [variance inflation factor (VIF) = 7.2 and 11.5, respectively], with their interaction term yielding a VIF of 20.3. Non-survivors and survivors who received advanced therapies share similar PC1 score distributions (a weighted composite of average PaO2 and cardiac index) and impaired haemodynamic profiles, including reduced ejection fraction, pulse pressures, and oxygen delivery indices. Conclusion: The association between early hyperoxia and mortality in VA-ECMO is primarily driven by underlying cardiac failure rather than direct oxygen toxicity. The availability of advanced therapies further modifies this relationship, underscoring the need to account for both native cardiac output and heart replacement strategies when evaluating optimal PaO2 targets and the independent effect of hyperoxia on VA-ECMO outcomes.

15 June 2025 in AACN Advanced Critical Care
Verified
Journal Article
Closed access
YWYu Wu
Yu Wu
JCJesus Casida
Jesus Casida

5 December 2025 in JHLT Open
Verified
Journal Article
Open access
YWYu Wu
Yu Wu
SBSylvie Baudart
Sylvie Baudart
RCRichard Cheng
Richard Cheng
KKKimberly Kallianos
Kimberly Kallianos
RRRyan Ruaysungnoen
Ryan Ruaysungnoen
LKLiviu Klein
Liviu Klein
Outflow graft obstruction (OGO) is a rare but potentially fatal complication of left ventricular assist device (LVAD) therapy. Timely diagnosis and intervention are critical to prevent hemodynamic compromise and death. We retrospectively reviewed 191 LVAD patients treated between January 2016 and April 2025. Seven (3.66%) had imaging-confirmed OGO. One died before intervention; 6 underwent intravascular ultrasound (IVUS)-guided stenting. LVAD flows, pressure gradient, and 12-month survival were analyzed. Patients had a mean age of 59.0 ± 13.8 years with a mean LVAD support duration of 63.6 ± 25.3 months. After stenting, mean LVAD flow improved from 1.98 to 4.70 L/min (p = 0.006), while gradients decreased from 74.67 to 31.67 mmHg (p = 0.027). No major complications occurred; all were discharged on warfarin and clopidogrel. The 12-month survival was 83.3% with 2 hemorrhagic strokes. Intravascular ultrasound-guided stenting of OGO is safe and effective. Timely intervention may improve survival. Further research is needed for optimal antiplatelet strategies in LVAD patients undergoing stenting for OGO.

20 October 2023 in Journal of the American Association of Nurse Practitioners
Verified
Journal Article
Closed access
YWYu Wu
Yu Wu
YNYuri Msn Nam
Yuri Msn Nam
IYIrina Msn Yurkova
Irina Msn Yurkova
ARAngel Dnp Rich
Angel Dnp Rich
LGLina Msn Gao
Lina Msn Gao
Heart failure (HF) is a chronic, progressive medical condition that can quickly cause deterioration of the patient's medical and functional status. Delay of HF diagnosis and improper treatment can lead to catastrophic patient outcomes. This case report describes a 62-year-old with HF with reduced ejection fraction secondary to nonischemic cardiomyopathy, s/p cardiac resynchronization therapy defibrillator in 2020. He presented to the emergency department for worsening shortness of breath and chest pain for 3 days and subsequently had cardiac arrest. The patient eventually underwent a successful implantation of left ventricular assist device as a bridge to transplant. Timely referral yields a better patient outcome. This case study illustrates a clinical pathway that can be used by primary care providers when considering referral of a patient with advanced HF (AHF) to an AHF center for management and possible advanced therapies.